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Abstract: In spite of the fact that the aging organism is the result of complex life-long gene/environment interactions, 
making peculiar the susceptibility to diseases and the response to drugs, pharmacogenetics studies are largely neglected in 
the aged. Altered response to drugs, cardiovascular and metabolic alterations, cancer and dementia are among the age as-
sociated ailments. The latter two are the major contributors to illness burden for the aged. Aging, dementia and cancer 
share a critical set of altered cellular functions in the response to DNA damage, genotoxic stress, and other insults. Aging 
in higher animals may be influenced by the balance of cell survival versus death, a decision often governed by checkpoint 
proteins in dividing cells. The paper is mainly focused on one of such proteins, p53 which has been recently shown to be 
involved in aging and Alzheimer’s Disease (AD). Within this reference frame we studied p53 in aged controls and de-
mented patients finding that with aging there is an increase of mutant like conformation state of p53 in peripheral blood 
cells, which is more pronounced in AD patients. As a result of such conformational change, p53 partially loses its activity 
and may become unable to properly activate an apoptotic program when cells are exposed to a noxious stimulus. Moreo-
ver we found that the tertiary structure of p53 and the sensitivity to p53-dependent apoptosis are affected by low concen-
trations of soluble beta amyloid, the peptide that accumulates in AD brain but also present in peripheral tissues. It is pos-
sible that p53 conformers may occur in the presence of misfolded molecules such as, but not limited to, beta amyloid. In 
particular at neuronal level the altered function of cell cycle proteins may affect synaptic plasticity rather then cell dupli-
cation. 
Key Words: pharmacogenetics, pharmacogenomics, aging, Alzheimer’s disease, beta-amyloid, conformationally altered p53, 
biomarker. 
PHARMACOGENETICS AND PHARMACOGENOM-
ICS: OPPORTUNITIES IN AGING STUDIES 
 The terms pharmacogenomics and pharmacogenetics 
tend to be used interchangeably, and a precise consensus 
definition of either remains elusive. However, pharmacoge-
netics refers to the role of genetic variation affecting drug 
response or adverse reactions to drugs [1]. While, pharmaco-
genomics better fits the definition of the science dealing with 
the analysis of genome (DNA) and of its products (RNA and 
proteins), aimed to correlate genomic information to cell or 
tissue response in order to find new targets for therapy, to 
develop new drugs and to study the response to them (see 
Drug Information Association website at www.diahome. 
org). 
 The aging organism is the result of complex life-long 
gene/environment interactions, making peculiar the suscepti-
bility to diseases and the response to drugs. Nowadays, al-
tered response to drugs, cardiovascular and metabolic altera-
tions, cancer and dementia are among the age associated  
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ailments. In this context, the shift from broad treatment 
strategies to more individually and genetically selected ap-
proaches would ensure that therapies would be both safer 
and more effective. In fact with an increased understanding 
about how genes and drugs interact, many patients could 
undergo a genetic test to predict their response and help en-
sure the medicine and dose is right at the first time. How-
ever, pharmacogenetic studies in aged patients are largely 
neglected, even if in elderly people pharmacokinetic and/or 
pharmacodynamic changes occur compared to younger peo-
ple, increasing the variability of the response. Aging is char-
acterized by a progressive loss of functional capacities of 
most if not all organs, a reduction in homeostatic mecha-
nisms and a response to receptor stimulation. Also, loss of 
water content and an increase of fat content in the body are 
reported. These changes have to be taken into consideration 
when the prescription of particular (cardiovascular or neuro-
psychiatric) drugs in elderly patients increases the risk of 
adverse drug reactions [2]. Pharmacodynamic changes in the 
elderly can result in greater, or sometimes even lesser, drug 
sensitivity than that seen in a younger individual. A greater 
drug sensitivity is particularly noticed with those drugs 
which act on the central nervous system, such as benzodi-
azepines [3]; on the other hand, ?-adrenergic agents are an  
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example of a reduction in responsiveness in elderly individu-
als [4]. Even if there is a general trend of greater pharma-
codynamic sensitivity in the elderly, however, this is not 
universal, and these age-related changes must be investigated 
agent-by-agent. Thus, inter-individual differences in drug 
response and adverse effects may be caused by variability in 
drug metabolism due to genetic polymorphisms, induction or 
inhibition of the metabolism by concomitant drug intake, 
environmental or physiological factors or pathological condi-
tions. As an example, the metabolism of donepezil, a selec-
tive acetylcholinesterase inhibitor used in the treatment of 
Alzheimer’s disease (AD), is dependent upon the genetic 
polymorphisms of the gene encoding CYP2D6, which has a 
large number of allelic variants, causing either absent, de-
creased or increased enzyme activity [5-6]. Varsaldi and 
coworkers [7] observed a large inter-individual variability in 
the concentration to dose ratio of donepezil among AD pa-
tients and noted that this variability partially correlated with 
the CYP2D6 genotype, thus suggesting that genetic poly-
morphism of CYP2D6 influences the metabolism and thera-
peutic outcome of donepezil. 
 Compared to pharmacogenetics, an abundant literature on 
pharmacogenomic studies is available even if not yet well 
organized. To date, pharmacogenomic studies are mainly 
focusing on many questions related to aging, concerning the 
research for aging genes, disease causing genes, longevity 
genes and are also pointing to identify susceptibility genes 
related to specific diseases, which allow health care provid-
ers to predict more accurately the risk of an individual of 
developing a specific disease [8-9]. A number of laboratories 
are making substantial and exciting progresses in the under-
standing of the genetics of aging and longevity; the principal 
aim of this studies are that these gene discoveries will lead to 
the identification of drug targets-drugs that would slow down 
the aging process and permit people to delay and perhaps 
escape age-associated diseases. Interestingly, by overviewing 
PubMed Citations from 1950 to 2008, the choice of model 
organism for aging is represented by Homo sapiens. In fact, 
while we found many data about developmental biology 
from worms, flies, and mice, there is a paucity of detailed 
information on the pathophysiology of aging, particularly in 
worms and flies; in contrast, there is a vast literature on these 
and all other aspects of human biology, including remarkable 
progress in human genetics [10]. 
 Aging and susceptibility to diseases associated with ag-
ing are likely to be influenced by thousands of genes [11-
12]. The vast amount of available literature generated in this 
field needs, however, a systematic revision and confirmation 
studies for the frequently contrasting results. Lacking genetic 
variations that predispose to diseases (so called “disease 
genes”) as well as having variations that confer disease resis-
tance (so called “longevity-enabling genes”) are probably 
both important to confer a remarkable survival advantage 
[13-14]. Conversely, defective functions of genes associated 
with longevity may influence premature neuronal survival 
[8].  
 About aging genes, the debate regarding the existance of 
genetic mutations actually able to either cause or accelerate 
aging is still open. Some researchers have proposed a geneti-
cally set biological clock which establishes when a species 
begins to age. Telomere length and/or telomerase function 
have been selected as time keeper candidates because of their 
potential role in regulating the number of cell divisions [15]. 
However, reduction in telomerase activity with older age 
might actually be a defensive measure against the increased 
potential for age-associated cancer. Another genetic defense 
against cancer is the p53 gene. Tyner and colleagues have 
noted an increase in p53 activity as a result of a deletion mu-
tation in the first six exons of the p53 gene associated with 
cancer prevention but also accelerated aging [16]. In fact, by 
generating transgenic mice carrying this mutation they found 
that mutant p53 mice exhibit an early onset of phenotypes 
associated with aging (reduced longevity, osteoporosis, gen-
eralized organ atrophy and a diminished stress tolerance), 
thus suggesting that p53 has a role in regulating organismal 
aging [16].  
 Among susceptibility genes, there are now numerous 
examples of genetic variations that substantially predispose 
to age-related disease (for example Alzheimer’s disease and 
apolipoprotein E ?4). The apolipoprotein E (APOE) gene is 
the most prevalent risk factor for AD, especially in those 
subjects harboring the APOE-4 allele, whereas carriers of the 
APOE-2 allele might be protected against dementia [8, 17-
18]. Because these variations are also associated with in-
creased mortality risk, it is likely that centenarians do not 
have many of these predisposing variations [18-20]. Within 
this context, Schachter and colleagues found that the fre-
quency of the apolipoprotein ?4 allele decreases markedly 
with advancing age, whereas, one of its counterparts, the ?2 
allele, becomes more frequent with advanced age among 
Caucasians [18]. 
STRATEGIES FOR PHARMACOGENOMIC STUDIES 
 Cardiovascular and metabolic alterations, cancer and 
dementia represent complex age-associated diseases with 
multiple gene variations. Within the context of complex dis-
eases, two different approaches are at the base of pharmaco-
genomic studies: one relies on a wide-genome screening and 
the other is driven by a specific hypothesis.  
 A genome-wide screening strategy underpins on the fact 
that, with the completion of the human genome project, sin-
gle nucleotide polymorphisms (SNP) genotyping is being 
undertaken in a large number of pharmacogenomic studies to 
identify variants associated with responses to specific drugs. 
Throughout the human genome, several types of genetic po-
lymorphisms can be found, but among these, SNPs are the 
most common polymorphisms and the attention of research-
ers has been focused on these in the last years. Genome-wide 
association studies have emerged as an increasingly effective 
tool for identifying genetic contributions to complex diseases 
and represent the next frontier to further understand the un-
derlying etiologic, biological, and pathologic mechanisms 
associated with chronic complex disorders. There have al-
ready been success stories for diseases such as diabetes mel-
litus [21]. Another recent example of wide-genome screen-
ing comes from the Framingham Heart Study (FHS) [22]. 
AD provides another good example of a complex age-
associated disease with multiple genetic etiologies, including 
Pharmacogenetics and Pharmagenomics, Trends Current Pharmaceutical Design, 2008, Vol. 14, No. 00    3 
specific sub-types inherited as autosomal dominant traits, as 
well as common forms related to the inheritance of suscepti-
bility genes. By performing genome-wide associations, an 
expectation is that the multiple contributing loci (as in AD) 
can be identified simultaneously, and then integrated into 
pathways contributing to a pathogenetic process for which 
drugs can be identified [23-24]. There is now experimental 
and clinical trial evidence to support this prediction [21, 25-
27]. Roses and coworkers described the design of high 
throughput disease-association SNP studies in AD [28], by 
confirming, from this initial screen that, among others, 
APOE4 is genetically associated with AD. Another screen-
ing strategy based on the use of microarray technology was 
also adopted for a new molecular test for AD in blood 
plasma [29]. Despite the great impact and the variety of 
available information, the screening strategy in pharmacoge-
nomic studies shows to date limitations yet. Currently, costs 
limit the widespread use of pharmacogenomics. Execution of 
pharmacogenomic studies is dependent on many pieces of 
information: access to accurate clinical and demographic 
data, DNA samples from well designed studies, SNPs, geno-
typing technologies, informatics technologies to handle large 
quantities of data, statistical methodologies for data analysis 
and interpretation. In this regard, other limitations in the 
progress of pharmacogenomics include tools used for col-
lecting, archiving, organizing and interpreting the huge 
amount of data generated in a pharmacogenomics study so 
that data from different experiments can be compared.  
 Specific hypothesis driven studies represent another ap-
proach in pharmacogenomics. Differently from wide-
genome screening, the strategy is focused on the knowledge 
of well-known genes involved in specific diseases. Taking as 
example AD, functional genomics studies in AD revealed 
that age of onset, brain atrophy, cognitive decline, apoptosis, 
immune function and amyloid deposition are associated with 
AD-related genes. The genetic defects identified in AD dur-
ing the past 25 years are represented by mutations in the 
amyloid precursor protein (APP) gene, on chromosome 21, 
in the presenilin 1 (PS1) gene, on chromosome 14, and in the 
presenilin 2 (PS2) gene, on chromosome 1 [8, 30-31]. In 
addition, polymorphic variants of risk in more than 200 dif-
ferent genes can increase neuronal vulnerability to premature 
death [18], with APOE gene (19q13.2) as the most prevalent 
risk factor for AD. Thus, focusing the study on one of these 
genes is possible to understand its specific role on specific 
events typical of AD. On the other hand, instead, all to-
gether, these genetic factors could interact in still unknown 
genetic networks leading to a cascade of events characterized 
by abnormal protein processing and misfolding with subse-
quent accumulation of abnormal proteins, excitotoxic reac-
tions, oxidative stress, mitochondrial injury, synaptic loss 
and deficiencies in neurotransmitter function [8, 30, 32-33]. 
 Pertaining to the context of aging, another example of 
hypothesis-driven study is based on checkpoint control by 
specific proteins. Aging in higher animals may be influenced 
by the balance of cell survival versus death, a decision often 
governed by checkpoint proteins in dividing cells. One of 
such proteins is p53; in mammals, p53 loss increases tumori-
genesis, while specific gain-of-function alleles reduce tumor 
incidence but accelerate aging, suggesting a trade-off be-
tween tumor surveillance and stem cell maintenance [34].  
p53: AGING AND CRITICAL DECISION ABOUT 
CELL FATE 
 The transcriptional network of p53-responsive genes 
produces proteins able to interact with a large number of 
other signal transduction pathways in the cell. p53 protein 
can trigger the onset either of reversible or permanent growth 
arrest [35-37] or of apoptosis [38-39]. However, the mecha-
nisms involved in the decision between these cellular re-
sponses are not well understood. Cell type, the presence of 
growth factors or oncogenes, the intensity of the stress sig-
nal, and the cellular level of p53 have been cited as impor-
tant factors in determining a specific p53-induced response 
[40-42]. Posttranslational modifications of the p53 gene have 
also been reported to influence the response observed [43]. 
For example, p53 phosphorylation by different kinases in 
response to stress can select for arrest or apoptosis, suggest-
ing the involvement of modifiers upstream of the p53 protein 
[43-44].  
 Once a cell has been damaged and the DNA damage re-
sponse and p53 are activated, a complex signaling network is 
engaged to result in a long-term cell fate decision. Rodier 
and coworkers reported an intriguing scheme showing four 
options adopted in normal mammalian cells [34]. Activation 
of cell cycle checkpoints by p53 leads to transient cell 
growth arrest [45]; p53 physically localizes to sites of DNA 
damage to promote repair [46] and simultaneously stimulates 
the transcription of direct e?ectors of the cell growth arrest 
(e.g. the cyclin-dependent kinase inhibitor p21) as well as 
e?ectors required for e?cient DNA repair of complex le-
sions that require longer processing (e.g. GADD45) [47]. At 
this point, several potential cellular outcomes can occur, 
most of which are heavily influenced by the cell type as well 
as the severity of the DNA lesions: transient cell cycle arrest 
(when DNA damage is not severe), defective repair (result-
ing in mutation, such as chromosomal aberrations), cell 
death (apoptosis) or permanent cell cycle arrest (cellular se-
nescence) [34]. Thus, p53 protects the genome by promoting 
the repair of potentially carcinogenic lesions in the DNA, 
thereby preventing mutations. In addition, p53 eliminates or 
arrests the proliferation of damaged or mutant cells by the 
processes of apoptosis and cellular senescence [48-49].  
 Loss of function in p53 is usually associated to many 
common human cancers. Mutant p53 is almost always defec-
tive for sequence-specific DNA binding, and thus for trans-
activation of genes upregulated by the wild-type protein 
[50]. Interestingly, when p53 is mutated in non-dividing 
cells, such as neurons, a dysfunctions accumulation can oc-
cur; Yang and coworkers, in fact, demonstrated the existence 
of aberrant neurons in AD brain, by showing that neurode-
generation is correlated to neurons reentering a lethal cell 
cycle [51].  
CONFORMATIONALLY ALTERED p53 IN AGED 
CONTROLS AND ALZHEIMER’S DISEASE PA-
TIENTS 
 We have studied p53 in aged controls and demented pa-
tients finding that with aging there is an increase of confor-
mationally altered p53, which is more pronounced in AD 
patients, to the point that it has been proposed as a putative 
biomarker in the early stages of the disease [52-53]. As a 
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result of such conformational change, p53 partially loses its 
activity and may become unable to properly activate an 
apoptotic program when cells are exposed to a noxious 
stimulus [52]. In this study we described and demonstrated 
an abnormal response of AD fibroblasts to an acute oxidative 
injury; in particular, fibroblasts from AD patients were found 
to be less vulnerable to the oxidative injury induced by H2O2 
in comparison with fibroblasts from non-AD subjects. Fibro-
blasts from sporadic AD patients represent an important 
starting point in the research for novel biomarkers because of 
their various abnormalities in metabolic and biochemical 
processes, which reflect some of the events in AD brain [54-
55]. Furthermore, on the basis of immunoprecipitation stud-
ies with conformation-specific p53 antibodies (PAb1620 and 
PAb240), which discriminated folded vs unfolded p53 terti-
ary structure, we found that in fibroblasts from AD patients a 
significant amount of total p53 assumes an unfolded tertiary 
structure; such alteration can compromise p53 response to an 
acute injury elicited by an excess of free radical production. 
Mutant p53 found in AD fibroblasts has been demonstrated 
to be independent from gene mutations on the basis of se-
quence analysis of the p53 gene, thus suggesting that one of 
the peripheral events associated to the disease is responsible 
for generating a conformationally altered p53 isoform [52]. 
In the attempt of investigating on the mechanism of such 
alteration, we assessed the contribution of APP metabolic 
products to the change in p53 conformational state. We 
found that the exposure to nanomolar concentrations of beta-
amyloid (A?) 1-40 peptide induced the expression of an un-
folded p53 protein isoform in fibroblasts derived from non-
AD subjects [56]. These data suggest that the tertiary struc-
ture of p53 and the sensitivity to p53-dependent apoptosis 
are influenced by low concentrations of soluble A?. On this 
basis, we hypothesised that low amounts of soluble A? in-
duce early pathological changes at cellular level that may 
precede the amyloidogenic cascade. One of these changes is 
the induction of a novel conformational state of p53. If low 
amounts of A? peptide, not resulting in cytotoxic effects, are 
responsible for p53 structure changes, it could be possible to 
consider the unfolded p53 both as an agent partecipating to 
the early pathogenesis and as a specific marker of the early 
stage of AD. 
 We then investigated the altered p53 isoform in more 
accessible cells, such as peripheral blood cells [53] to deter-
mine the frequency and the extent of this defect in AD pa-
tients and to explore the possibility to develop an assay to 
validate conformationally altered p53 as a putative peripheral 
marker of the disease. The identification of new biological 
markers, to date, can be greatly useful both to improve diag-
nostic accuracy and/or to monitor the efficacy of putative 
therapies, since the confirmatory diagnosis of AD is possible 
only post mortem, based on recognition and quantification of 
senile plaques and neurofibrillary tangles. Furthermore, we 
set up a rapid and easy flow-cytometric approach to identify 
the different expression of conformationally altered p53 be-
tween AD and non-AD subjects. Differently from other data 
in literature regarding the development of biomarkers for AD 
or in CSF [57-58] or in blood [59-60], the main advantage of 
our study was the development of a biological sample prepa-
ration procedure as well as of an analytical method that 
could permit a routine analysis. If this method should be 
confirmed in a larger population and further validated, it 
could be useful in improving the knowledge regarding the 
clinical diagnosis of AD, because we could have the possi-
bility to recognize AD and non-AD cases, by starting from 
small blood volumes thus using a less invasive technique 
[53]. Interestingly, we observed that the expression of con-
formationally altered p53, both in controls and AD, is an age 
dependent event, while it is independent from the length of 
illness and from the MMSE score; this linear correlation 
with age would suggest that its significance would be differ-
ent within specific age interval segments. In order to deter-
mine the diagnostic performance of conformationally altered 
p53 as an AD marker, we worked out sensitivity and speci-
ficity within different age intervals and found that these val-
ues were more significant in subjects up to 70 years of age 
(sensitivity of 90% to discriminate AD patients from non 
demented aged individuals at a specificity value of 77%) 
compared with the corresponding values for individuals 
older than 70 years [53]. Although the age stratification is 
admittedly a post-hoc analysis it serves to indicate that the 
putative marker proposed appears to be more important in 
the younger patients, also considering that the positivity to 
p53 conformational mutant induced a calculated O.R. of 29.2 
for AD. The fact that the most significant differences are 
observed in the youngest patients indicate that the measure-
ment of conformational mutant p53 may be usefully applied 
to detect AD at the early stages, perhaps applied to those 
patients falling in the ill defined category of mild cognitive 
impairment (MCI). Whether this expression of conforma-
tionally altered p53 will be suitable as an adjunctive diagnos-
tic tool to predict the conversion from MCI to AD is under 
investigation. 
 In addition, in order to better characterize the nature of 
this different expression between AD and control subjects, 
we also evaluated whether the expression of conformational 
mutant p53 showed a correlation with the APOE status. We 
recruited a population of 75 patients with sporadic AD, 69 
healthy age-matched controls (CTR) (Table 1). Genomic 
DNA was extracted from peripheral leukocytes by proteinase 
K digestion and standard phenol/chlorophorm extraction 
procedure. The APOE gene polymorphisms (isoforms APOE 
?2, APOE ?3, APOE ?4) were determined by Hha I restric-
tion endonuclease digestion of PCR products, according to 
Hixson and Vernier [61]. After having determined APOE 
gene polimorphisms, we then divided this population in four 
groups, control subjects and AD patients with and without 
the ?4 allele, to establish if the presence of the ?4 allele 
might further affect the expression of mutant-like p53. The 
expression of mutant conformational p53 was independent 
from distribution of ?4 allele of APOE, thus highlighting that 
the presence of ?3/?4 and ?4/?4 genotypes was not linked to 
a higher expression of p53 conformational status (Fig. 1). 
AD patients without the ?4 allele showed a higher expression 
of mutant-like p53 compared to respective controls (percent 
of PAb positive cells, mean ± SD; control subjects without 
APOE?4: 22.8 ± 12.2; AD without APOE?4: 39.3 ± 15.0; 
AD without APOE?4 versus respective control P < 0.0001). 
The comparison of the APOE?4 positive cases did not show 
a statistically significant difference between AD and the re-
spective controls possibly because of the small size of the 
control sample (8 patients). On the other hand, complexively 
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the p53 may be a marker useful in the ?4 negative younger 
patients (< 70 years). 
 
Table 1. Demographic and Clinical Variables of all the Sub-
jects 
 AD CTR 
N (M;F) 75 (20;55) 69 (34;35) 
mean age + SD 79 + 9 78 + 10 
L.O.I. (month) 53 + 26  
MMSE 14 + 6 28 + 1.6 
N: number; M: male; F: female; L.O.I.: length of illness; MMSE: Mini-Mental State 
Examination. Data are expressed as mean + standard deviation. 
CONCLUSIONS/PERSPECTIVES 
 Aging in higher animals may be influenced by the bal-
ance of cell survival versus death, at least in part regulated 
by a fine timing of checkpoint proteins and preservation of 
DNA integrity and correct repair [62-63]. With our study we 
propose an example pointing to a peculiar aspect of pharma-
cogenetic/pharmacogenomics research in aging and age as-
sociated diseases, that is the possibility to define novel tar-
gets for therapeutic interventions aimed to chekpoint pro-
teins. p53 has been recently shown to be involved in aging 
and AD. Recent evidence suggests that increased p53 activ-
ity can, at least under some circumstances, promote organ-
ismal aging [34]. We showed a link between AD pathology 
and conformationally altered p53 [52-54], by finding that 
with aging a higher increase of an unfolded state of p53 in 
AD patients compared to age-matched controls occurs. What 
can be the contribution of a conformational change of a pro-
tein to the aging process is under investigation. We could 
also address the issue whether a generalization of this phe-
nomenon within the context of the “gain and loss of func-
tion” of protein conformers will be possible. It is worth to 
underline that the observation that aging and AD interfere 
with proteins controlling the duplication and cell cycle, such 
as p53, is interesting and may lead to the speculation that, in 
senescent neurons, derangements in proteins commonly 
dealing with cell cycle control and apoptosis could affect 
neuronal plasticity and functioning rather then cell duplica-
tion.  
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Fig. (1). Correlation between the APOE status and conformational mutant p53. 
Box plot of the amount of conformational mutant p53 (%) expressed in peripheral blood cells of all the subjects classified on the basis of 
their APOE genotypes. The figure is based on a rather innovative application in flow cytometry on peripheral blood cells. Venous blood 
samples were collected from a group of 75 patients with sporadic AD and 69 healthy age-matched controls (CTR). Peripheral blood mono-
nuclear cells were then analyzed for the expression of conformationally altered p53 with a flow cytometer. The APOE gene polymorphisms 
(isoforms APOE ?2, APOE ?3, APOE ?4) were determined by Hha I restriction endonuclease digestion of PCR products. Bonferoni multiple 
comparison test was used to compare values in different groups. Differences were considered significant when a p-value < 0.05 was attained. 
***p < 0.001 vs control without ?4 allele. We previously published [53] the observation that the elevated conformationally altered p53 was 
specific for AD and not observed in other neurodegenerative diseases, such as Parkinson’s disease, vascular dementia and sopranuclear 
palsy. 
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